GlassScriptPhysician profile
Adam Arceneaux
NPI 1538571252
$5,661.92
in general payments reported to CMS, 2019-2025
35 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $776 · 2021: $674 · 2022: $1,092 · 2023: $487 · 2024: $685 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.59 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $776.00 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $545.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $504.49 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.90 | 2019-2024 | Jardiance |
| Allergan, INC. | $255.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.22 | 2019-2022 | |
| Abbvie INC. | $231.03 | 2019-2025 | Vraylar |
| Smith+Nephew, INC. | $228.12 | 2021-2024 | Iodosorb Ointment 40g USA, Collagenase Santyl, Renasys Go V2 Home |
| Esperion Therapeutics, INC. | $219.37 | 2021-2022 | |
| Glaxosmithkline, LLC. | $212.37 | 2019-2022 | |
| Organogenesis INC. | $194.42 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $183.08 | 2019-2021 | |
| Amgen INC. | $167.67 | 2019-2020 | |
| Abbott Laboratories | $151.02 | 2022-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $136.21 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $128.36 | 2022 | |
| Vanda Pharmaceuticals INC. | $124.27 | 2019-2025 | Fanapt |
| Pfizer INC. | $113.75 | 2019-2025 | |
| Astellas Pharma US INC | $111.49 | 2019-2023 | |
| Hydrofera LLC | $111.29 | 2024 | Hydrofera Blue |
| Takeda Pharmaceuticals U.S.A., INC. | $94.63 | 2019-2020 | |
| Bsn Medical INC | $91.00 | 2023 | |
| Redhill Biopharma INC. | $82.03 | 2022 | |
| Amarin Pharma, INC. | $69.45 | 2019-2020 | |
| Genzyme Corporation | $64.18 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $63.84 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $47.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.73 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $29.56 | 2019 | |
| Boston Scientific Corporation | $20.00 | 2021 | |
| Reprise Biomedical, INC. | $18.83 | 2025 | Miro3d |
| Mylan Specialty L.P. | $15.03 | 2019 | |
| Vertiflex, INC. | $14.33 | 2019 | |
| Genentech USA, INC. | $13.39 | 2019 | |
| Optinose US, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Arceneaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.